Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by cpacon Feb 08, 2020 9:27am
268 Views
Post# 30661961

RE:RE:timelines from info available at present

RE:RE:timelines from info available at presentHere's the thing, the actual total pain medication market is measured in the hundreds and hundreds of billions, it's just the indication that were testing on that's estimated at 11B...  

The reality is that you could get more than 10% of the market and the other drugs in the pipeline can grow the total addressable market meaningfully.  In fact, in one of their presentations, one slide asked, should everyone be on daily therapy with one of ATE's drugs?  (I.e. my doctor told me NOT to go on a daily Aspirin because he worried about the the risk of stomach and intestinal ulcers... scary stuff)  However ANTIBE'S drugs could provide ALL the benefits of low dose daily aspirin without the GI RISKS.  When I read this, I realized ANTIBE had the potential to be a complete MONSTER. 

The major caveat here is TIME... ATE will see some great bumps up in the share price over the course of this year... but to fully realize their vision will take multiple years... that said, the payoff could be just... staggering.  :)   
Bullboard Posts